Silvia Zibellini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Silvia Zibellini has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Luca Arcaini
Department of Molecular Medicine University of Pavia Pavia Italy
18 shared publications - Marco Paulli
Department of Molecular Medicine University of Pavia Pavia Italy
14 shared publications - Marzia Varettoni
Division of Hematology Fondazione IRCCS Policlinico San Matteo and University of Pavia Pavia Italy
10 shared publications Cristiana Pascutto
Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy
9 shared publicationsMario Cazzola
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
9 shared publicationsEmanuela Boveri
Department of Pathology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
8 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Histopathology
Clinical, histopathological and molecular characterization of mantle cell lymphoma with MALToma‐like presentation
Aims: Recently a subset of mantle cell lymphoma (MCL) with predominant extranodal disease and frequent involvement of mucosa‐associated lymphoid tissues (MALT‐MCL) has been described, showing a more indolent course and favourable prognosis than classical nodal MCL (CN‐MCL). Herein we detail the clinicopathological features of a single centre series of 12 MCL patients with primary MALT presentation, including immunogenetic profile and mutational landscape. Methods and results: The most frequently affected extranodal sites were nasopharynx and Waldeyer's ring (five patients, 41.7%), gastrointestinal tract (three patients), ocular adnexa and salivary glands (two patients each), and a single case with maxillary sinus involvement. All patients were treated, achieving a complete (seven patients) or partial response (five patients). Isolated extranodal relapse occurred in three patients; three patients died of disease. At median 12‐years follow‐up, OS was 11.3 years; 10‐years OS and PFS were 65.5% and 54.7%, respectively. Waldeyer's ring involvement was associated with increased deaths for disease and shorter 10‐years OS (33.3% vs 85.7% in patients lacking Waldeyer's ring involvement). All cases carried t (11;14)(q13;q32)‐ CCND1‐IGH translocation whereas IGH clonal rearrangements were detected in eight patients; six cases, including all patients with Waldeyer's ring involvement, carried unmutated or minimally mutated rearrangements, whereas two cases involving stomach and ocular adnexa showed highly mutated rearrangements. Targeted NGS mutational analysis identified ATM mutations in two cases but did not reveal recurrent alterations involving TP53 , CDKN2A or CCND1 . Conclusions: Our data seem to confirm that MALT‐MCL shares histological, phenotypic and IGHV rearrangements with CN‐MCL, but pursues a more indolent clinical course than CN‐MCL, thus suggesting a putative different genetic pathway.
- 10 November 2026
- Published by Wiley in Histopathology
Open AccessClinical, histopathological and molecular characterization of mantle cell lymphoma with MALToma‐like presentation
Aims: Recently a subset of mantle cell lymphoma (MCL) with predominant extranodal disease and frequent involvement of mucosa‐associated lymphoid tissues (MALT‐MCL) has been described, showing a more indolent course and favourable prognosis than classical nodal MCL (CN‐MCL). Herein we detail the clinicopathological features of a single centre series of 12 MCL patients with primary MALT presentation, including immunogenetic profile and mutational landscape. Methods and results: The most frequently affected extranodal sites were nasopharynx and Waldeyer's ring (five patients, 41.7%), gastrointestinal tract (three patients), ocular adnexa and salivary glands (two patients each), and a single case with maxillary sinus involvement. All patients were treated, achieving a complete (seven patients) or partial response (five patients). Isolated extranodal relapse occurred in three patients; three patients died of disease. At median 12‐years follow‐up, OS was 11.3 years; 10‐years OS and PFS were 65.5% and 54.7%, respectively. Waldeyer's ring involvement was associated with increased deaths for disease and shorter 10‐years OS (33.3% vs 85.7% in patients lacking Waldeyer's ring involvement). All cases carried t (11;14)(q13;q32)‐ CCND1‐IGH translocation whereas IGH clonal rearrangements were detected in eight patients; six cases, including all patients with Waldeyer's ring involvement, carried unmutated or minimally mutated rearrangements, whereas two cases involving stomach and ocular adnexa showed highly mutated rearrangements. Targeted NGS mutational analysis identified ATM mutations in two cases but did not reveal recurrent alterations involving TP53 , CDKN2A or CCND1 . Conclusions: Our data seem to confirm that MALT‐MCL shares histological, phenotypic and IGHV rearrangements with CN‐MCL, but pursues a more indolent clinical course than CN‐MCL, thus suggesting a putative different genetic pathway.
- Open Access
- 24 December 2021
- Published by Springer Nature in Genes & Immunity
- Vol. 23 (1) , 51-56
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients
Toll-like receptors (TLR) are crucial components in the initiation of innate immune responses to a variety of pathogens, triggering the production of pro-inflammatory cytokines and type I and II interferons, which are responsible for innate antiviral responses. Among the different TLRs, TLR7 recognizes several single-stranded RNA viruses including SARS-CoV-2. We and others identified rare loss-of-function variants in X-chromosomal TLR7 in young men with severe COVID-19 and with no prior history of major chronic diseases, that were associated with impaired TLR7 signaling as well as type I and II IFN responses. Here, we performed RNA sequencing to investigate transcriptome variations following imiquimod stimulation of peripheral blood mononuclear cells isolated from patients carrying previously identified hypomorphic, hypofunctional, and loss-of-function TLR7 variants. Our investigation revealed a profound impairment of the TLR7 pathway in patients carrying loss-of-function variants. Of note, a failure in IFNγ upregulation following stimulation was also observed in cells harboring the hypofunctional and hypomorphic variants. We also identified new TLR7 variants in severely affected male patients for which a functional characterization of the TLR7 pathway was performed demonstrating a decrease in mRNA levels in the IFNα, IFNγ, RSAD2, ACOD1, IFIT2, and CXCL10 genes.
- 24 December 2021
- Published by Springer Nature in Genes & Immunity
- Vol. 23 (1) , 51-56
Open AccessRare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients
Toll-like receptors (TLR) are crucial components in the initiation of innate immune responses to a variety of pathogens, triggering the production of pro-inflammatory cytokines and type I and II interferons, which are responsible for innate antiviral responses. Among the different TLRs, TLR7 recognizes several single-stranded RNA viruses including SARS-CoV-2. We and others identified rare loss-of-function variants in X-chromosomal TLR7 in young men with severe COVID-19 and with no prior history of major chronic diseases, that were associated with impaired TLR7 signaling as well as type I and II IFN responses. Here, we performed RNA sequencing to investigate transcriptome variations following imiquimod stimulation of peripheral blood mononuclear cells isolated from patients carrying previously identified hypomorphic, hypofunctional, and loss-of-function TLR7 variants. Our investigation revealed a profound impairment of the TLR7 pathway in patients carrying loss-of-function variants. Of note, a failure in IFNγ upregulation following stimulation was also observed in cells harboring the hypofunctional and hypomorphic variants. We also identified new TLR7 variants in severely affected male patients for which a functional characterization of the TLR7 pathway was performed demonstrating a decrease in mRNA levels in the IFNα, IFNγ, RSAD2, ACOD1, IFIT2, and CXCL10 genes.
- 9 September 2019
- Published by Wiley in American Journal of Hematology
- Vol. 94 (11) , 1193-1199
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network
Lymphoplasmacytic lymphoma (LPL) is usually associated with a serum IgM paraprotein, corresponding to Waldenström's Macroglobulinemia (WM). Cases presenting with IgG or IgA, or without a monoclonal protein are extremely rare. We analyzed clinical characteristics, frontline treatment, and the outcome of 45 patients with non‐IgM LPL, and compared them with a control group of WM patients. The median age was similar, with significantly higher prevalence of females in non‐IgM LPL, than in WM patients (60% vs 39%, P = .016). Patients with non‐IgM LPL more frequently presented with lymphadenopathies (53% vs 15%, P < .001), splenomegaly (22% vs 8%, P = .015) or extranodal involvement (20% vs 8%, P = .05). In non‐IgM LPL a serum monoclonal protein and bone marrow infiltration were less common than in WM patients (69% and 84% of cases respectively, P < .001 for both comparisons). The MYD88 (L265P) mutation was found in 8/19 patients using allele‐specific polymerase chain reaction. A CXCR4 mutation was found in 4/17 cases using Sanger. In 16 patients we performed targeted next‐generation sequencing of genes MYD88, CXCR4, ARID1‐A, KMT2D, NOTCH2, TP53, PRDM1, CD79B, TRAF3, MYBBP1A, TNFAIP3. Seven patients (44%) had a MYD88 mutation (S219C in one), four (25%) a CXCR4 mutation, three (19%) a KMT2D mutation, one (6%) a TP53 mutation and one (6%) a TRAF3 mutation. With a median follow‐up of 55.7 months, 36 non‐IgM LPL patients (80%) were treated. Non‐IgM LPL patients received more frequently anthracycline‐containing regimens, as compared with WM patients, who mainly received alkylating‐based therapies. Five‐year overall survival (OS) was 84%, similar to that of WM patients.
- 9 September 2019
- Published by Wiley in American Journal of Hematology
- Vol. 94 (11) , 1193-1199
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network
Lymphoplasmacytic lymphoma (LPL) is usually associated with a serum IgM paraprotein, corresponding to Waldenström's Macroglobulinemia (WM). Cases presenting with IgG or IgA, or without a monoclonal protein are extremely rare. We analyzed clinical characteristics, frontline treatment, and the outcome of 45 patients with non‐IgM LPL, and compared them with a control group of WM patients. The median age was similar, with significantly higher prevalence of females in non‐IgM LPL, than in WM patients (60% vs 39%, P = .016). Patients with non‐IgM LPL more frequently presented with lymphadenopathies (53% vs 15%, P < .001), splenomegaly (22% vs 8%, P = .015) or extranodal involvement (20% vs 8%, P = .05). In non‐IgM LPL a serum monoclonal protein and bone marrow infiltration were less common than in WM patients (69% and 84% of cases respectively, P < .001 for both comparisons). The MYD88 (L265P) mutation was found in 8/19 patients using allele‐specific polymerase chain reaction. A CXCR4 mutation was found in 4/17 cases using Sanger. In 16 patients we performed targeted next‐generation sequencing of genes MYD88, CXCR4, ARID1‐A, KMT2D, NOTCH2, TP53, PRDM1, CD79B, TRAF3, MYBBP1A, TNFAIP3. Seven patients (44%) had a MYD88 mutation (S219C in one), four (25%) a CXCR4 mutation, three (19%) a KMT2D mutation, one (6%) a TP53 mutation and one (6%) a TRAF3 mutation. With a median follow‐up of 55.7 months, 36 non‐IgM LPL patients (80%) were treated. Non‐IgM LPL patients received more frequently anthracycline‐containing regimens, as compared with WM patients, who mainly received alkylating‐based therapies. Five‐year overall survival (OS) was 84%, similar to that of WM patients.
- 5 July 2019
- Published by Wiley in British Journal of Haematology
- Vol. 187 (4) , 441-446
A risk‐stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders
Summary: IgM monoclonal gammopathies of undetermined significance (IgM MGUS) are associated with a risk of progression to Waldenström macroglobulinaemia (WM) or other lymphoproliferative disorders (LPD) of 1–2% per year. We analysed 176 consecutive patients with IgM MGUS to evaluate risk factors for progression. With a median follow‐up of 83 months (1214 person‐years), 15 patients (8·5%) progressed to WM (n = 14) or marginal zone lymphoma (n = 1). The rate of progression was 1·32% per year (95% confidence interval [CI] 0·80–2·20). The serum monoclonal protein concentration and the MYD88 mutation were independent risk factors for progression (Hazard ratio [HR] 23·3, 95% CI 2·0–273·3, P = 0·012 and HR 24·4, 95% CI 2·2–275·3, P = 0·010, respectively). The cumulative incidence of progression, while considering death as a competing event, was 11·6% at 5 years and 38·0% at 10 years in MYD88‐mutated patients with a serum monoclonal protein of 10 g/l or higher, as compared with 0% at 5 years and 1·1% at 10 years for patients with none or one risk factor. This risk‐stratification model is able to identify a subset of patients with IgM MGUS at high risk of progression to WM or LPD who deserve a lifelong follow‐up.
- 5 July 2019
- Published by Wiley in British Journal of Haematology
- Vol. 187 (4) , 441-446
A risk‐stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders
Summary: IgM monoclonal gammopathies of undetermined significance (IgM MGUS) are associated with a risk of progression to Waldenström macroglobulinaemia (WM) or other lymphoproliferative disorders (LPD) of 1–2% per year. We analysed 176 consecutive patients with IgM MGUS to evaluate risk factors for progression. With a median follow‐up of 83 months (1214 person‐years), 15 patients (8·5%) progressed to WM (n = 14) or marginal zone lymphoma (n = 1). The rate of progression was 1·32% per year (95% confidence interval [CI] 0·80–2·20). The serum monoclonal protein concentration and the MYD88 mutation were independent risk factors for progression (Hazard ratio [HR] 23·3, 95% CI 2·0–273·3, P = 0·012 and HR 24·4, 95% CI 2·2–275·3, P = 0·010, respectively). The cumulative incidence of progression, while considering death as a competing event, was 11·6% at 5 years and 38·0% at 10 years in MYD88‐mutated patients with a serum monoclonal protein of 10 g/l or higher, as compared with 0% at 5 years and 1·1% at 10 years for patients with none or one risk factor. This risk‐stratification model is able to identify a subset of patients with IgM MGUS at high risk of progression to WM or LPD who deserve a lifelong follow‐up.
- 23 May 2019
- Published by American Society of Hematology in Blood
- Vol. 133 (21) , 2251-2253
JAK inhibitors and risk of B-cell lymphomas
In this issue of Blood, Pemmaraju et al explored the potential correlation between therapy with JAK inhibitors and the risk of a subsequent lymphoma in patients with myeloproliferative neoplasms (MPNs).1
- 23 May 2019
- Published by American Society of Hematology in Blood
- Vol. 133 (21) , 2251-2253
JAK inhibitors and risk of B-cell lymphomas
In this issue of Blood, Pemmaraju et al explored the potential correlation between therapy with JAK inhibitors and the risk of a subsequent lymphoma in patients with myeloproliferative neoplasms (MPNs).1
- Open Access
- 10 April 2019
- Published by Wiley in American Journal of Hematology
- Vol. 94 (7) , E185-E188
Ruxolitinib treatment and risk of B‐cell lymphomas in myeloproliferative neoplasms
- 10 April 2019
- Published by Wiley in American Journal of Hematology
- Vol. 94 (7) , E185-E188
Open AccessRuxolitinib treatment and risk of B‐cell lymphomas in myeloproliferative neoplasms
- Open Access
- 5 October 2017
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (12) , 2077-2085
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
We analyzed MYD88 and CXCR4 mutation status of 260 patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance using allele-specific real time quantitative polymerase chain reaction and Sanger sequencing, respectively. A subgroup of 119 patients was further studied with next-generation sequencing of 11 target genes (MYD88, CXCR4, ARID1A, KMT2D, NOTCH2, TP53, PRDM1, CD79B, TRAF3, MYBBP1A, and TNFAIP3). MYD88 (L265P) was found at diagnosis in 91% of patients with Waldenström macroglobulinemia and in 60% of patients with IgM monoclonal gammopathy of undetermined significance using allele-specific polymerase chain reaction analysis. MYD88 mutations other than the classical L265P (V217F, S219C and M232T) were found in four cases by next-generation sequencing. Waldenström macroglobulinemia patients with wild-type MYD88 had a distinct clinical phenotype characterized by less bone marrow infiltration (P=0.01) and more frequent extramedullary involvement (P=0.001) compared to patients with mutated MYD88. Patients with wild-type MYD88 did not show additional mutations in the other target genes. CXCR4 mutations were found by Sanger sequencing in 22% of patients with Waldenström macroglobulinemia. With next-generation sequencing, a CXCR4 mutation was detected in 23% of patients with Waldenström macroglobulinemia and 9% of those with IgM monoclonal gammopathy of undetermined significance. Asymptomatic Waldenström macroglobulinemia patients harboring a CXCR4 mutation had a shorter treatment-free survival (51 months) than that of patients with wild-type CXCR4 (median not reached) (P=0.007). Analysis of variant allele frequencies indicated that CXCR4 mutations were present in the dominant clone in the majority of cases. Recurrent somatic mutations of KMT2D were found in 24% of patients with Waldenström macroglobulinemia and 5% of patients with IgM monoclonal gammopathy of undetermined significance and were primarily subclonal.
- 5 October 2017
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 102 (12) , 2077-2085
Open AccessPattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
We analyzed MYD88 and CXCR4 mutation status of 260 patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance using allele-specific real time quantitative polymerase chain reaction and Sanger sequencing, respectively. A subgroup of 119 patients was further studied with next-generation sequencing of 11 target genes (MYD88, CXCR4, ARID1A, KMT2D, NOTCH2, TP53, PRDM1, CD79B, TRAF3, MYBBP1A, and TNFAIP3). MYD88 (L265P) was found at diagnosis in 91% of patients with Waldenström macroglobulinemia and in 60% of patients with IgM monoclonal gammopathy of undetermined significance using allele-specific polymerase chain reaction analysis. MYD88 mutations other than the classical L265P (V217F, S219C and M232T) were found in four cases by next-generation sequencing. Waldenström macroglobulinemia patients with wild-type MYD88 had a distinct clinical phenotype characterized by less bone marrow infiltration (P=0.01) and more frequent extramedullary involvement (P=0.001) compared to patients with mutated MYD88. Patients with wild-type MYD88 did not show additional mutations in the other target genes. CXCR4 mutations were found by Sanger sequencing in 22% of patients with Waldenström macroglobulinemia. With next-generation sequencing, a CXCR4 mutation was detected in 23% of patients with Waldenström macroglobulinemia and 9% of those with IgM monoclonal gammopathy of undetermined significance. Asymptomatic Waldenström macroglobulinemia patients harboring a CXCR4 mutation had a shorter treatment-free survival (51 months) than that of patients with wild-type CXCR4 (median not reached) (P=0.007). Analysis of variant allele frequencies indicated that CXCR4 mutations were present in the dominant clone in the majority of cases. Recurrent somatic mutations of KMT2D were found in 24% of patients with Waldenström macroglobulinemia and 5% of patients with IgM monoclonal gammopathy of undetermined significance and were primarily subclonal.
- Top Cited PapersOpen Access
- 22 June 2017
- Published by American Society of Hematology in Blood
- Vol. 129 (25) , 3371-3378
Clinical significance of somatic mutation in unexplained blood cytopenia
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
- 22 June 2017
- Published by American Society of Hematology in Blood
- Vol. 129 (25) , 3371-3378
Top Cited PapersOpen AccessClinical significance of somatic mutation in unexplained blood cytopenia
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
- 20 October 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (30) , 3627-3637
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
Purpose: The genetic basis of myelodysplastic syndromes (MDS) is heterogeneous, and various combinations of somatic mutations are associated with different clinical phenotypes and outcomes. Whether the genetic basis of MDS influences the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT) is unclear. Patients and Methods: We studied 401 patients with MDS or acute myeloid leukemia (AML) evolving from MDS (MDS/AML). We used massively parallel sequencing to examine tumor samples collected before HSCT for somatic mutations in 34 recurrently mutated genes in myeloid neoplasms. We then analyzed the impact of mutations on the outcome of HSCT. Results: Overall, 87% of patients carried one or more oncogenic mutations. Somatic mutations of ASXL1, RUNX1, and TP53 were independent predictors of relapse and overall survival after HSCT in both patients with MDS and patients with MDS/AML (P values ranging from .003 to .035). In patients with MDS/AML, gene ontology (ie, secondary-type AML carrying mutations in genes of RNA splicing machinery, TP53-mutated AML, or de novo AML) was an independent predictor of posttransplantation outcome (P = .013). The impact of ASXL1, RUNX1, and TP53 mutations on posttransplantation survival was independent of the revised International Prognostic Scoring System (IPSS-R). Combining somatic mutations and IPSS-R risk improved the ability to stratify patients by capturing more prognostic information at an individual level. Accounting for various combinations of IPSS-R risk and somatic mutations, the 5-year probability of survival after HSCT ranged from 0% to 73%. Conclusion: Somatic mutation in ASXL1, RUNX1, or TP53 is independently associated with unfavorable outcomes and shorter survival after allogeneic HSCT for patients with MDS and MDS/AML. Accounting for these genetic lesions may improve the prognostication precision in clinical practice and in designing clinical trials.
- 20 October 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (30) , 3627-3637
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
Purpose: The genetic basis of myelodysplastic syndromes (MDS) is heterogeneous, and various combinations of somatic mutations are associated with different clinical phenotypes and outcomes. Whether the genetic basis of MDS influences the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT) is unclear. Patients and Methods: We studied 401 patients with MDS or acute myeloid leukemia (AML) evolving from MDS (MDS/AML). We used massively parallel sequencing to examine tumor samples collected before HSCT for somatic mutations in 34 recurrently mutated genes in myeloid neoplasms. We then analyzed the impact of mutations on the outcome of HSCT. Results: Overall, 87% of patients carried one or more oncogenic mutations. Somatic mutations of ASXL1, RUNX1, and TP53 were independent predictors of relapse and overall survival after HSCT in both patients with MDS and patients with MDS/AML (P values ranging from .003 to .035). In patients with MDS/AML, gene ontology (ie, secondary-type AML carrying mutations in genes of RNA splicing machinery, TP53-mutated AML, or de novo AML) was an independent predictor of posttransplantation outcome (P = .013). The impact of ASXL1, RUNX1, and TP53 mutations on posttransplantation survival was independent of the revised International Prognostic Scoring System (IPSS-R). Combining somatic mutations and IPSS-R risk improved the ability to stratify patients by capturing more prognostic information at an individual level. Accounting for various combinations of IPSS-R risk and somatic mutations, the 5-year probability of survival after HSCT ranged from 0% to 73%. Conclusion: Somatic mutation in ASXL1, RUNX1, or TP53 is independently associated with unfavorable outcomes and shorter survival after allogeneic HSCT for patients with MDS and MDS/AML. Accounting for these genetic lesions may improve the prognostication precision in clinical practice and in designing clinical trials.
- Top Cited PapersOpen Access
- 8 September 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (10) , 1408-1417
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Key Points: Risk assessment is crucial in patients with CMML because survival may range from a few months to several years. Integrating clinical features, morphology, and genetic lesions significantly improves risk stratification in CMML.
- 8 September 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (10) , 1408-1417
Top Cited PapersOpen AccessIntegrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia
Key Points: Risk assessment is crucial in patients with CMML because survival may range from a few months to several years. Integrating clinical features, morphology, and genetic lesions significantly improves risk stratification in CMML.